Titan Pharmaceuticals Schedules Conference Call to Review Second Quarter 2011 Financial Results and Probuphine Phase 3 Clinical Study Results
Leading Addiction Medicine Experts to Join Company for Call
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 08/09/11 -- Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that it will host a live conference call at 11 a.m. ET / 8 a.m. PT on Tuesday, August 16, 2011. Titan will provide the Company's financial results as of June 30, 2011 and, as previously announced, discuss results of its recently reported positive Phase 3 clinical trial of Probuphine in patients with opioid dependence. The call will be hosted by Sunil Bhonsle, President, Katherine Beebe, Ph.D., Executive Vice President and Chief Development Officer, and Marc Rubin, M.D., Executive Chairman. Joining the Titan management team for the call will be:
- Walter Ling, M.D., Professor of Psychiatry and Director, Integrated Substance Abuse Programs at the David Geffen School of Medicine at UCLA and a lead investigator in the Probuphine Phase 3 study
- Richard N. Rosenthal, M.D., Chairman of Psychiatry at St. Luke's-Roosevelt Hospital Center, a teaching hospital of Columbia University, past president of the American Academy of Addiction Psychiatry and a lead investigator in the Phase 3 study
Highlights of the second quarter financial results and the data from the confirmatory Phase 3 study of Probuphine will be included in press releases to be issued prior to the call.
The live webcast of the call may be accessed by visiting the Titan website at www.titanpharm.com. The call can also be accessed by dialing 1-888-206-4836 Participant code: 6514332 five minutes prior to the start time. A replay of the call will be available on the Company website approximately two hours after completion of the call and will be archived for two weeks.
About Titan Pharmaceuticals
For information concerning Titan Pharmaceuticals, Inc., please visit the Company's website at www.titanpharm.com.
The press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product development or commercialization, the uncertainty of patent protection for the Company's intellectual property or trade secrets, and the Company's ability to obtain additional financing. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release.
CONTACT: Titan Pharmaceuticals, Inc. Sunil Bhonsle 650-244-4990 President Pure Communications Dan Budwick 973-271-6085 email@example.com
Source: Titan Pharmaceuticals, Inc.
Released August 9, 2011